20:03 , Jul 6, 2018 |  BioCentury  |  Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic...
19:35 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round on April 18 led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors...
21:14 , Apr 18, 2018 |  BC Extra  |  Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round Wednesday led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors also participated....
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG)

Infectious disease INDICATION: Viral infection; melanoma Mouse studies suggest PSGL-1 inhibitors could help treat chronic viral infections or melanoma. In a mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection, knockout of PSGL-1 decreased viral...
07:00 , Oct 29, 2015 |  BC Innovations  |  Emerging Company Profile

Rebuilding the barrier

Leuvas Therapeutics Inc. , Mountain View, Calif. Approved therapies for epilepsy control seizures by suppressing firing, but the drugs are ineffective in about one third of patients, produce psychological side effects, and don't address the...
07:00 , Apr 16, 2015 |  BC Innovations  |  Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Treating inflammation using mesenchymal stem cells (MSCs) overexpressing P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG), Sialyl-LewisX (SLeX) and IL-10 MSCs overexpressing PSGL-1, SLeX and IL-10...
07:00 , Sep 24, 2012 |  BioCentury  |  Finance

Selexys' sickle sale

Selexys' sickle sale MPM Capital is betting that veterans from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) can turn the firm's investment in hematology play Selexys Pharmaceuticals Corp. into a takeout within three years. Last week, Selexys raised...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

AbGenomics, Boehringer Ingelheim deal

In December, AbGenomics said it will regain rights to AbGn-168H from Boehringer Ingelheim, effective Feb. 13. The companies mutually terminated the 2005 deal giving Boehringer exclusive, worldwide rights to develop and commercialize the humanized mAb...
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis P selectin (SELP; CD62P); P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG) Studies in mice suggest that inhibiting PSGL-1 or its receptor SELP could...